Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 13/20 | 0.37 |
| ▸ | HTR2C | P28335 | 13/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763877 | 1.00 | PARP1 (0.38) | PARP1HTR2BHTR2CHTR6HTR3E | |
| Hydrochloric Acid SCHEMBL21855144 | 0.98 | PARP1 (0.37) | PARP1HTR2BHTR2CHTR6HTR3E | |
| SCHEMBL20986376 | 0.92 | HTR2C (0.39) | PARP1HTR2BHTR2CHTR6HTR3E | |
| SCHEMBL20986373 | 0.92 | HTR2C (0.39) | PARP1HTR2BHTR2CHTR6HTR3E | |
| SCHEMBL16786083 | 0.92 | HTR2C (0.39) | PARP1HTR2BHTR2CHTR6HTR3E | |
| Hydrochloric Acid SCHEMBL16764419 | 0.90 | HTR2C (0.39) | PARP1HTR2BHTR2CHTR6HTR3E | |
| Hydrochloric Acid SCHEMBL16764417 | 0.90 | HTR2C (0.39) | PARP1HTR2BHTR2CHTR6HTR3E | |
| Trifluoroacetic Acid SCHEMBL28856904 | 0.88 | PARP1 (0.37) | PARP1HTR2BHTR2CEGFRLCK | |
| SCHEMBL24832835 | 0.84 | HTR6 (0.44) | PARP1HTR2BHTR2CHTR6HTR3E | |
| SCHEMBL16786080 | 0.84 | PARP1 (0.40) | PARP1HTR2BHTR2CHTR6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051475-A | 9-Membered heteroaryl compounds, pharmaceutical compositions containing the same, and methods of preparing and using the same | 广东弘烨医药科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-31 | — | — | US | disclosed |
| CN-115557933-B | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-4342892-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-115557933-A | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-3077388-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198280-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | PARP1 704/4885HTR2B 4506/4885HTR2C 4250/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | PARP1 704/4885HTR2B 4506/4885HTR2C 4250/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | PARP1 669/4885HTR2B 4543/4885HTR2C 4335/4885 |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | BTK, ZAP70, SYK | PARP1 3454/4885HTR2B 3458/4885HTR2C 3796/4885 |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | PARP1 892/4885HTR2B 3267/4885HTR2C 3688/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | PARP1 704/4885HTR2B 4506/4885HTR2C 4250/4885 |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | PARP1 892/4885HTR2B 3267/4885HTR2C 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.